No Data
No Data
Oruka Therapeutics Reports Strong 2024 Financial Results
We're Not Very Worried About Oruka Therapeutics' (NASDAQ:ORKA) Cash Burn Rate
Oruka Therapeutics at Risk: Navigating Licensing Challenges and Partner Reliance
Sector Update: Health Care
TD Cowen Maintains Oruka Therapeutics(ORKA.US) With Buy Rating
Oruka Therapeutics Says ORKA-002 Preclinical Data Support Potential Extended Dosing Intervals